GMP Oversight Collaboration Helps FDA Plan, But Not Avoid, Foreign Inspections
Executive Summary
FDA has improved planning efforts with information borrowed from European and Australian authorities, but an inspection collaboration between the three countries could not help it avoid some inspections.
You may also be interested in...
FDA Mutual Reliance with EU on Inspections Is Slow Going
FDA still does over 40% of its inspections in Europe even as it acknowledges it must spend the money elsewhere.
FDA Mutual Reliance With EU On Inspections Is Slow Going
FDA still does over 40% of its inspections in Europe even as it acknowledges it must spend the money elsewhere.
Practice Makes Good: FDA, EMA Focus On CROs As GCP Info Sharing Improves
FDA and EMA need more time working together before they can rely on each other’s Good Clinical Practice inspection findings, a recent joint report concludes.